MOUNTAIN VIEW, Calif., Nov. 22, 2011 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced they will present at the 23rd Annual Piper Jaffray Health Care Conference at the New York Palace Hotel, New York, NY. Omnicell Speakers: Randall A. Lipps, founder, chairman, president & CEO and Rob Seim, vice president & CFO Date:Tuesday, November 29, 2011Time: 2:30 p.m. ETLocation: New York Palace Hotel, New York, NYAvailability: The audio-webcast of the live presentation will be accessible at: http://ir.omnicell.com/events.cfm Following the conference, a replay of the audio-webcast will be archived for 30 days on the Omnicell website. About Omnicell Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of automated and business information solutions enabling hospitals and healthcare systems to streamline the medication administration process and manage costly medical supplies for increased operational efficiency and enhanced patient safety. Through seamless integration with a hospital's existing IT infrastructure, Omnicell solutions empower healthcare facilities to achieve comprehensive automation of medication and supply management from the arrival at the loading dock to the patient's bedside. Omnicell also provides healthcare facilities with business analytics software designed to improve medication diversion detection and regulatory compliance. Since 1992, more than 2,200 hospital customers worldwide have relied on Omnicell's medication automation, supply chain, and hospital analytics solutions to increase patient safety, improve efficiency and address changing healthcare regulations while providing effective control of costs, charge capture for payer reimbursement and inventory management of medications and supplies. For more information about Omnicell, please visit www.omnicell.com OMCL-E
Since this summer's market low, small-cap stocks have been outperforming large-cap stocks. Here are small caps with 'persistently strong top-line growth and improving fundamentals,' according to RBC Capital Markets.